$RGNX

Regenxbio Inc (RGNX) shares rose 7.1% premarket after director Gregory Ciongoli bought 102,603 shares at $9.14-$9.36 each, totaling over $950,000. Ciongoli also received restricted stock units and stock options. His total ownership increased to 118,035 shares.

Ciongoli Gregory Austin purchased 102,603 shares of REGENXBIO Inc. (RGNX) at an average of $9.25 ($9.14–$9.36, $0.95M total) across 2 trades over 2026-08-26 to 2026-08-27.

REGENXBIO Inc. (RGNX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EXHIBIT 99.1 REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli ROCKVILLE, Md., August 25, 2026 – REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming ca

REGENXBIO Inc. (Nasdaq: RGNX) appointed Greg Ciongoli to its Board of Directors, effective August 25, 2026. Ciongoli brings biotech investing and strategic expertise. Jerry Karabelas and Jean Bennett retired from the Board. The company is preparing for growth with its gene therapy pipeline.

Johnson Fistel is investigating REGENXBIO (RGNX) for potential securities law violations after the FDA placed its RGX-121 gene therapy program on clinical hold due to MRI findings. The company does not expect to resubmit its application soon. Investors who suffered losses are encouraged to join the investigation.

Regenxbio's stock fell 25% to $8.05 after the FDA placed a clinical hold on its gene therapy candidate RGX-121 due to spinal nodules in five trial participants. The company halted near-term BLA resubmission plans for RGX-121 but will file a BLA for its Duchenne treatment this quarter and expects wet AMD trial results in Q4. According to the company, the nodules are likely benign, but the FDA required further review.

U.S. futures decline ahead of Nvidia (NVDA) earnings and Fed Chair Kevin Warsh's speech. Tech stocks underperform, with memory and semiconductor stocks falling. Alibaba (BABA) raises $10.2B in Hong Kong, while PDD Holdings (PDD) gains 2% on earnings. Regenxbio (RGNX) drops 25% after FDA clinical hold. Treasury bond buybacks and inflation data are key focuses this week.

Regenxbio (RGNX) stock fell 24.3% to $8.12 after the FDA placed a clinical hold on its RGX-121 gene therapy due to safety concerns. The company delayed resubmitting the therapy's Biologics License Application. Analysts had recently downgraded the stock. The broader market showed minor declines, and peers were unaffected.

REGENXBIO Inc. (NASDAQ:RGNX) shares dropped 35% after the FDA placed a clinical hold on its gene therapy RGX-121 for MPS II due to asymptomatic spine MRI findings in five participants. The company does not expect to resubmit the BLA soon but remains focused on other candidates, including Duchenne and retinal disease treatments. REGENXBIO plans to submit a BLA for Duchenne this quarter and announce wet AMD data in Q4.

H.C. Wainwright cut its Regenxbio (NASDAQ:RGNX) price target to $23 from $26 and kept a Buy rating after Regenxbio completed a common stock offering in July 2026. The firm cited Q2 2026 revenue of $108.0 million and net income of $22.7 million ($0.43/share), plus AbbVie’s $100 million milestone. Regenxbio plans a rolling BLA module for RGX-202 in Q3 2026, targeting accelerated approval in H2 2027.